Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally.
Jazz Pharmaceuticals stock last closed at $109.46, up 1.89% from the previous day, and has decreased 20.64% in one year. It has overperformed other stocks in the Biotechnology industry by 0.02 percentage points. Jazz Pharmaceuticals stock is currently +2.68% from its 52-week low of $106.61, and -25.39% from its 52-week high of $146.70.
There are currently 62.35M JAZZ shares outstanding. The market capitalization of JAZZ is $6.82B. In the last 24 hours, 480,574 JAZZ shares were traded.
You will need an online brokerage account in order to access the NASDAQ market and buy JAZZ stock.
Based on our research, eToro is the best place to buy stocks. eToro gives you:
Get $10 towards your purchase of shares by creating an account with eToro today.
Open eToro AccountNow that you've selected your brokerage, it's time to fill out some personal info so you can invest in JAZZ stock today.
Now that you've created your account on our top ranked stock app, you can securely and quickly fund your account:
Check out the tutorial below if you need help depositing money into your new brokerage account.
Once you have decided on the best place to buy Jazz Pharmaceuticals stock, it's important to analyze their stock before you invest, so you can wrap your head around the risk and upside.
WallStreetZen was designed to help average investors do more accurate fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on JAZZ's stock page.
Investors use many financial metrics, analyses, models, and charts to gauge JAZZ's true value.
Using relative valuations ratios:
You can do additional valuation analysis on JAZZ's stock here.
Out of 11 Equities analysts who track JAZZ, the consensus analyst rating on JAZZ is a Strong Buy
It's important to note that analyst forecasts are not stock recommendations, nor are they investment advice.
Annabel Samimy, a top 5% analyst from Stifel Nicolaus maintains JAZZ with a strong buy rating and raises their JAZZ price target from $225.00 to $230.00, on Mar 15, 2024.
Stifel Nicolaus's Annabel Samimy raised their price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) by 2.2% from $225 to $230 on 2024/03/15. The analyst maintained their Strong Buy rating on the stock.
Ahead of Jazz Pharmaceuticals' Zanidatamab Virtual R&D Day event on 2024/03/19, Samimy said that their price target move followed "Stifel Nicolaus laying out its initial expectations for Zanidatamab in the three currently studied indications of second-line BTC, first-line GEA, and HER2+/HR+ locally advanced breast cancer."
Zanidatamab is being developed in multiple clinical trials as a targeted treatment option for patients with solid tumors that express HER2.
The FDA has granted Breakthrough Therapy designation for zanidatamab development in patients with previously treated HER2 gene-amplified biliary tract cancers (BTC), and two Fast Track designations for zanidatamab: one as a single agent for refractory BTC and one in combination with standard of care chemotherapy for first-line gastroesophageal adenocarcinoma (GEA). Additionally, zanidatamab has received Orphan Drug designations from the FDA for the treatment of BTC and GEA, as well as Orphan Drug designation from the European Medicines Agency for the treatment of BTC and gastric cancer. Zanidatamab was also granted Breakthrough Therapy designation from the Center for Drug Evaluation (CDE) in China. [From here]
Oren Livnat, a bottom 8% analyst from HC Wainwright & Co. maintains JAZZ with a buy rating and lowers their JAZZ price target from $204.00 to $200.00, on Mar 14, 2024.
Ashwani Verma, a top 33% analyst from UBS maintains JAZZ with a hold rating and lowers their JAZZ price target from $135.00 to $131.00, on Mar 1, 2024.
Balaji Prasad, a bottom 7% analyst from Barclays maintains JAZZ with a strong buy rating and lowers their JAZZ price target from $235.00 to $230.00, on Mar 1, 2024.
Gregory Renza, a top 4% analyst from RBC Capital reiterates JAZZ with a buy rating and maintains their JAZZ price target from $195.00 to $195.00, on Feb 29, 2024.
You can dig deeper into what analysts are saying on the Jazz Pharmaceuticals stock forecast page.
Last year, JAZZ earnings were $414.83M. In the last five year, JAZZ's earnings have gone up by -2.54% per year. This was slower than the Biotechnology industry average of 17.13%.
Last year, JAZZ revenue was $3.83B. In the last 5 year, JAZZ's revenue has grown by 15.19% per year. This was slower than the Biotechnology industry average of 28.56%.
Find out more about JAZZ's earnings and revenue performance here.
In the last 12 months, executives and large shareholders at JAZZ have sold more shares than they have bought.
Renee D. Gala, President COO of JAZZ, was the latest JAZZ insider to sell. They sold $200,004.56 worth of JAZZ stock on Apr 5, 2024.
Learn more about who owns JAZZ shares here.
No, Jazz Pharmaceuticals doesn't provide an income stream by paying out dividends.
One of the primary reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other community members have to say.
You have two main types of orders:
Press the Open button and your broker will execute the order.
If you require more help with investing in stocks on eToro, click the how to video below:
Now that you own some shares in JAZZ, you'll want to keep up with your investment.
Make a watchlist to track your JAZZ stock.
To reiterate, here are the 6 steps to buy Jazz Pharmaceuticals stock:
If you are looking for a place to buy stocks, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to get the latest news on your investment in Jazz Pharmaceuticals, add JAZZ to your watchlist by clicking the button below.